Company Overview of Immunocore Limited
Immunocore Limited, a bio-technology company, discovers and develops bio-therapeutics for the treatment of cancer, viral diseases, and autoimmune diseases. It offers T cell receptors, a peptide antigen that presented on the surface of cells by human leukocyte antigen molecules; and IMCgp100, a novel bi-specific immunotherapeutic for the treatment of malignant melanoma. Immunocore Limited was formerly known as Avidex Limited and changed its name to Immunocore Limited in October 2008. The company was founded in 1999 and is based in Abingdon, United Kingdom.
91 Park Drive
Abingdon, OX14 4RY
Founded in 1999
Key Executives for Immunocore Limited
Executive Chairman and Interim Chief Executive Officer
Founder and Chief Scientific Officer
Chief Business Officer and Director
Head of Business Development
Compensation as of Fiscal Year 2014.
Immunocore Limited Key Developments
Immunocore Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 03:15 PM
Nov 20 14
Immunocore Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 03:15 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Eli Lilly and Company and Immunocore Limited Enter Immunotherapy Agreement to Co-Discover and Co-Develop Novel Cancer Therapies
Jul 16 14
Eli Lilly and Company and Immunocore Limited announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology, the companies will seek to use the power of the body's own immune system to attack cancer cells. ImmTACs have shown potential to direct a patient's T cells to specifically target the cancerous cells, avoiding damage to healthy cells. Under the terms of the agreement, Immunocore will receive an upfront fee of $15 million per program for the discovery of novel ImmTACs against jointly-selected cancer targets in order to generate preclinical candidate packages. If Lilly accepts a preclinical candidate package to develop and potentially commercialize, Immunocore will receive an opt-in fee of $10 million and will have an option to continue co-development with Lilly on a cost-sharing and profit-sharing basis. If Immunocore does not exercise its option, it will be entitled to potential future significant milestone and royalty payments.
Immunocore Limited Presents at Citi European Healthcare Conference, Jun-18-2014
May 23 14
Immunocore Limited Presents at Citi European Healthcare Conference, Jun-18-2014 . Venue: Stirling Square, 5-7 Carlton Gardens, London SW1Y 5AD, United Kingdom. Speakers: Eva-Lotta Allan, CBO.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|